Please note that this is a preliminary program.
The program definition will continue over the coming months, with the help of Advisory Board members.
The final program will be available in May 2023. In particular, the content of the general sessions and “Focus on...” sessions will be defined on the basis of the abstract evaluation.
These sessions offer participants an opportunity to discuss clinical cases that they encounter on a day-to-day basis in their work as lymphoma specialists but for which there might be no clearly defined best practices.
Each of the five sessions (Aggressive NHL, Indolent NHL and CLL, Hodgkin Lymphoma, Difficult Pathological Cases, Paediatric Lymphoma) will involve world-renowned specialists who will bring their knowledge and expertise to the benefit of our participants.
Presenters and discussants to be announced.
Two Educational symposia will take place in parallel on Wednesday morning before the official opening of the Conference. Each symposium will extensively address a specific topic, explained in 3 lectures (20 minutes each) by experts who will explore and scrutinize different aspects of the chosen topics. Attendees will have the possibility to ask questions to the speakers and ample time will devoted also to the discussion among the experts.
Diffuse Large B-Cell Lymphomas (DLBCL)
Lecture 1: CAR T-cells: Gilles Salles, New York, NY (USA)
Lecture 2: Bispecific antibodies: Martin Hutchings, Copenhagen (Denmark)
Lecture 3: New agents: Ranjana H. Advani, Stanford, CA (USA)
Chronic Lymphocytic Leukemia (CLL)
Lecture 1: Biology: Nicholas Chiorazzi, Manhasset, NY (USA)
Lecture 2: First line therapy: Michael Hallek, Cologne (Germany)
Lecture 3: Therapy of relapsed disease and Richter's Syndrome: John F. Seymour, Melbourne (Australia)
These sessions are simultaneous sessions highlighting abstracts of scientific value that have not been selected for oral presentations during the general sessions. These sessions run in parallel and each session focuses on a particular topic. Each one-hour session consists of 6 presentations of 10 minutes each, including discussions and Q&A.
These sessions will be defined on the basis of abstract evaluation.
Based on the abstracts received and accepted for oral presentations, general sessions will be devoted either to specific subtypes of lymphoid neoplasia (e.g. mantle cell lymphomas, follicular lymphomas, T-cell lymphomas, etc) or to the presentation of laboratory and clinical research data grouped around a biologic topic (e.g. microenvironment, signaling pathway, surface antigens).
The program will also include two sessions devoted entirely to basic and translational research topics ("Dissecting lymphomas at the single cell level" and "Epigenetic mechanisms and targeted therapies in B- and T-cell lymphomas”).
Abstracts related to these topics will be evaluated for presentation during these two sessions.
The Keynotes lectures are among the most significant moments of the Congress and are dedicated to three prominent individuals engaged in the study of lymphomas, in the development of therapeutic strategies targeting lymphomas and in particular, those recognised for their important contributions throughout the history of the ICML. These lectures are assigned to distinguished scientists and researchers by the Organizing Committee, with the help of the Advisory Board, on the basis of various criteria.
“Henry Kaplan Memorial Lecture”
This celebrates the achievements of a lifetime career and acknowledges the activity that has led to significant and appreciated results over the years.
Henry Kaplan was a pioneer in the study and treatment of lymphomas and inspired the choice of Lugano as venue for the ICML.
“Genetic and Microenvironmental Features of Large B-cell Lymphomas”: Margaret A. Shipp, Boston, MA (USA)
Wednesday, June 14, Room A Palazzo dei Congressi
“Gianni Bonadonna Memorial Lecture”
This covers topics particularly important for translational research and marks our collaboration with the European School of Oncology (ESO).
Gianni Bonadonna developed what has become the standard therapy for Hodgkin lymphoma (ABVD), which has maintained its importance for decades and he was one of the 3 oncologists who first decided to dedicate a congress entirely to malignant lymphomas.
“Elucidating the enigmatic pathobiology of Hodgkin lymphoma”: Ralf Küppers, Essen (Germany)
Thursday, June 15, Room A Palazzo dei Congressi
“John Ultmann Memorial Lecture”
This deals with clinical topics and is organized in collaboration with the American Association for Cancer Research (AACR).
John Ultmann was a pioneer in the precise staging of Hodgkin's disease and its application as a guide for treatment. He was a member of the ICML Organizing Committee from its first edition until the year of his death in 2000.
“25 years of antibody treatments for lymphoma”: Peter W.M. Johnson, Southampton (GB)
Friday, June 16, Room A Palazzo dei Congressi
“Meet the Professor” sessions are 45-minutes lessons (30 minutes frontal lecture and 15 minutes discussion) that allow participants to meet internationally recognized experts and gain a deeper insight into topics of particular interest.
Out of 12 sessions, 8 are repeated twice and 4 are offered only once.
No registration is required but early arrival is recommended to ensure the possibility to enter the halls (participation is subject to availability of seats).
- Advances in PET and radiomics
Sally Barrington, London (UK)
- Cutaneous T-cell lymphoma – focus on some problems and some solutions
Helmut Beltraminelli, Locarno (Switzerland)
- CNS lymphoma (primary and secondary) treatment and prophylaxis
Kate Cwynarski, London (UK)
- Mantle Cell
Martin Dreyling, Munich (Germany)
- Update on Follicular Lymphomas
Jonathan W. Friedberg, Rochester, NY (USA)
- Peripheral T-cell lymphomas
Steven M. Horwitz, New York, NY (USA)
- Are we reaching the maximum cure rate for Hodgkin lymphoma?
Peter W.M. Johnson, Southampton (UK)
- Germinal center in the genesis of lymphomas
Laura Pasqualucci, New York, NY (USA)
- Lymphoma in pregnancy
Fedro A. Peccatori, Milan (Italy)
- Reappraisal of role of RT in lymphoma treatment
Lena Specht, Copenhagen (Denmark)
- Marginal zone lymphomas
Emanuele Zucca, Bellinzona (CH)
- Post-transplantation lymphoproliferative disorders in children (PTLD)
Thomas Gross, Aurora, CO (USA)
The collection of articles written by speakers of the Educational symposia and Meet the Professor sessions represents the content of the Educational Book, published by John Wiley and Sons, Ltd. and distributed onsite to the attendees.
AACR-ICML joint session: "Technology that will change lymphoma understanding and care"
The positive and fruitful collaboration between AACR and ICML, which started in 2015, continues and is particularly evident in this co-organized session.
Here the program of the 2023 session:
1) Single cell: Katia Basso, New York, NY (USA)
2) Circulating tumor DNA (liquid biopsy): Davide Rossi, Bellinzona (Switzerland)
3) AI-based trial design: Olivier Elemento, New York, NY (USA)
Sessions devoted to Lymphoma Radiotherapy
Organised in collaboration with the International Lymphoma Radiation Oncology Group (ILROG), these workshops represent an opportunity for interaction and continuous learning not only for radiation oncologists, but also for medical oncologists and haematologists.
The topics of the 2023 workshops will be:
- Artificial intelligence and machine learning in lymphomas and in radiotherapy.
Special Lecture by the IBSA Foundation for scientific research
As in the last 3 editions of ICML, attendees will again have the possibility to attend a special lecture organised by the IBSA Foundation Forum for scientific research. The scientific content will be defined in collaboration with the Foundation for Institute of Oncology Research (IOR).
This is a lecture held at the closure of the Scientific Program that summarizes and highlights the themes addressed during the congress.
The participants will receive a series of hints and considerations that will facilitate the identification and understanding of the new knowledge presented and discussed in Lugano.
James O. Armitage, Omaha, NE (USA)